HPV Vaccine Price to Plummet for Poor Countries

Merck, GlaxoSmthKline will offer them for less than $5
By Kevin Spak,  Newser Staff
Posted May 9, 2013 1:51 PM CDT
HPV Vaccine Price to Plummet for Poor Countries
In this file photo, one dose of an HPV vaccine is displayed in Austin, Texas.   (AP Photo/Harry Cabluck, File)

Two of the world's biggest drug companies have agreed to slash the price of their HPV vaccines—which currently cost around $130 a dose in the US—down to less than $5 in some developing nations, the companies announced today. Thanks to a deal negotiated by the nonprofit GAVI Alliance, Merck and GlaxoSmithKline have agreed to provide a few million cheap doses of their respective cervical cancer-fighting products for demo programs in countries including Kenya, Ghana, Laos, and Madagascar, the New York Times reports.

GAVI, which is funded by the Bill and Melinda Gates foundation, is hoping to have the lower prices ($4.50 for Merck's drug and $4.60 for Glaxo's) in place in 40 countries, giving some 30 million girls access to the vaccine. But the deal won't include poor countries in Latin America, because they have wealthier neighbors, and Doctors Without Borders says it's "disappointing" that prices aren't even lower. "Why are the pharmaceutical companies still making profits off the backs of the poorest countries?" a specialist for the group asked. (More GlaxoSmithKline stories.)

Get the news faster.
Tap to install our app.
Install the Newser News app
in two easy steps:
1. Tap in your navigation bar.
2. Tap to Add to Home Screen.